JOHN C. CRAWHALL, M.D., PH.D.
This content is PDF only. Please click on the PDF icon to access.
It has been 25 years since the first patient was given penicillamine for the treatment of Wilson's disease. The International Symposium on Penicillamine, recently held in Miami, reviewed the present scope of its therapeutic uses. Penicillamine remains the preferred treatment for Wilson's disease, with only one other drug, triethylethylene tetramine dihydrochloride, as a second line of treatment. Less information is available on penicillamine as a chelating agent for other metals, but in limited applications it seems to have some value in the treatment of lead poisoning and mercury poisoning.
In 1962, Crawhall and colleagues (1) introduced use of penicillamine for
CRAWHALL JC. Penicillamine: Twenty-Five Years Later. Ann Intern Med. 1980;93:367–368. doi: 10.7326/0003-4819-93-2-367
Download citation file:
Published: Ann Intern Med. 1980;93(2):367-368.
Emergency Medicine, Encephalopathy, Gastroenterology/Hepatology, Liver Disease, Neurology.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use